Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.50 |
| ▸ | LOX | P28300 | 6/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263952 | 0.81 | SLC6A4 (0.48) | IRAK4SLC6A2SLC6A4SLC6A3TLR9 | |
| SCHEMBL25300735 | 0.80 | LOXL2 (0.66) | LOXL2LOXLOXL3CSNK2A1 | |
| SCHEMBL6263948 | 0.80 | SLC6A4 (0.37) | IRAK4SLC6A2SLC6A4SLC6A3TLR9 | |
| SCHEMBL6223830 | 0.78 | LOXL2 (0.49) | LOXL2LOXIRAK4LOXL3CSNK2A1 | |
| SCHEMBL5262266 | 0.77 | MAP3K12 (0.48) | IRAK4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL448817 | 0.77 | SLC6A4 (0.36) | IRAK4SLC6A2SLC6A4SLC6A3TLR9 | |
| SCHEMBL27571943 | 0.75 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL23868364 | 0.73 | IRAK4 (0.44) | IRAK4SLC6A4 | |
| SCHEMBL25209760 | 0.71 | LOXL2 (0.57) | LOXL2LOXLOXL3CSNK2A1 | |
| SCHEMBL30931754 | 0.71 | LOXL2 (0.57) | LOXL2LOXLOXL3CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1313464-C | Substituted alkylamine derivatives and methods of use | AMGEN INC (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1519921-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005279-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |